Table 2.
Summary of siRNA Therapies in CRLM Clinical Trials.
| Intervention | Target | Administration route | Status | Phase | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| Drug: ALN-VSP02 | VEGF and KSP | IV | Completed (2011) Completed (2012) | Phase 1 | NCT00882180 NCT01158079 |
| Drug: Atu027 | PKN3 | IV | Completed (2012) | Phase 1 | NCT00938574 |
| Drug: TKM 080301 | PLK1 | Catheter | Completed (2012) | Phase 1 | NCT01437007 |
| Biological: APN401 | Cblb | IV | Completed (2020) | Phase 1 | NCT03087591 |
| Drug: NBF-006 | GSTP1 | IV | Recruiting | Phase 1 | NCT03819387 |
| Drug: siRNA-EphA2-DOPC | EphA2 | IV | Active, not recruiting | Phase 1 | NCT01591356 |
| Drug: CALAA-01 | RRM2 | IV | Terminated (2012) | Phase 1 | NCT00689065 |
| Drug: DCR-MYC | MYC | IV | Terminated (2016) | Phase 1 | NCT02110563 |